Correlation between lncRNA MIR155HG and pulmonary function in patients with COPD and its auxiliary diagnosis value for AECODP

doi:10.3969/j.issn.1673-8640.2024.01.006

Abstract

Abstract:

Objective To investigate the correlation between long non-coding RNA（lncRNA） MIR155HG and pulmonary function in patients with chronic obstructive pulmonary disease（COPD） and its auxiliary diagnosis value for acute exacerbation of chronic obstructive pulmonary disease（AECOPD）. Methods A total of 117 COPD patients treated in Nanyang Central Hospital from October 2018 to March 2021 were enrolled，which included 60 patients in stable phase as stable phase group and 57 patients with AECOPD as AECOPD group，and 60 healthy subjects were enrolled as control group. The general data were collected. Pulmonary function [forced expiratory volume in one second（FEV₁），forced vital capacity（FVC）] was evaluated，and FEV₁/FVC% was calculated. The level of lncRNA MIR155HG in peripheral blood mononuclear cell（PBMC） was determined. Logistic regression analysis was used to analyze the factors of AECOPD. Receiver operating characteristic（ROC） curve was used to analyze the efficiency of various indicators in the diagnosis of AECOPD. Results White blood cell（WBC）count，neutrophil percentage（NEUT%），procalcitonin（PCT），C-reactive protein（CRP），fibrinogen（Fib） and lncRNA MIR155HG level in PBMC were decreased in turn in AECOPD group，stable phase group and control group（P<0.05）. FEV₁ and FEV₁/FVC% were increased in turn（P<0.05）. The level of lncRNA MIR155HG in PBMC in AECOPD group and stable phase group was positively correlated with WBC count，NEUT%，PCT，CRP and Fib（P<0.001），and they were negatively correlated with FEV₁ and FEV₁/FVC%（P<0.001）. Increased lncRNA MIR155HG and decreased FEV₁ were risk factors for AECOPD [odds ratios（OR）were 2.381，0.682，95% confidence intervals（CI）were 1.526-3.715，0.531-0.876]. The areas under curves（AUC） of FEV₁ and lncRNA MIR155HG single and combined determinations to predict AECOPD were 0.826，0.854 and 0.939，respectively. Conclusions The increased level of lncRNA MIR155HG in PBMC of COPD patients is related to clinical indicators and pulmonary function，which is expected to become an early predictive marker of AECOPD.

Key words: Long non-coding RNA MIR155HG, Chronic obstructive pulmonary disease, Peripheral blood mononuclear cell

CLC Number:

R446.7

ZHANG Feifei, WANG Jingwen, ZHANG Yuexin, ZHENG Dawei, MEN Xiang. Correlation between lncRNA MIR155HG and pulmonary function in patients with COPD and its auxiliary diagnosis value for AECODP[J]. Laboratory Medicine, 2024, 39(1): 31-36.

Figures/Tables 7

References 17

[1]	SCARAMUZZO G, OTTAVIANI I, VOLTA C A, et al. Mechanical ventilation and COPD:from pathophysiology to ventilatory management[J]. Minerva Med, 2022, 113(3):460-470.
[2]	XIAO Y, GU X, NIU H, et al. Associations of residential greenness with lung function and chronic obstructive pulmonary disease in China[J]. Environ Res, 2022, 209:112877. DOI URL
[3]	XIA J, GU S, LEI W, et al. High-flow nasal cannula versus conventional oxygen therapy in acute COPD exacerbation with mild hypercapnia:a multicenter randomized controlled trial[J]. Crit Care, 2022, 26(1):109. DOI
[4]	LI N, LIU Y, CAI J. LncRNA MIR155HG regulates M1/M2 macrophage polarization in chronic obstructive pulmonary disease[J]. Biomed Pharmacother, 2019, 117:109015. DOI URL
[5]	中华医学会呼吸病学分会慢性阻塞性肺疾病学组. 慢性阻塞性肺疾病诊治指南(2013年修订版)[J]. 中华结核和呼吸杂志, 2013, 36(4):255-264.
[6]	慢性阻塞性肺疾病急性加重AECOPD诊治专家组. 慢性阻塞性肺疾病急性加重(AECOPD)诊治中国专家共识(2017年更新版)[J]. 国际呼吸杂志, 2017, 37(14):1041-1057.
[7]	YANG I A, JENKINS C R, SALVI S S, et al. Chronic obstructive pulmonary disease in never-smokers:risk factors,pathogenesis,and implications for prevention and treatment[J]. Lancet Respir Med, 2022, 10(5):497-511. DOI URL
[8]	KAUR M, CHANDEL J, MALIK J, et al. Particulate matter in COPD pathogenesis:an overview[J]. Inflamm Res, 2022, 71(7-8):797-815. DOI
[9]	HSU C W, SUK C W, HSU Y P, et al. Sphingosine-1-phosphate and CRP as potential combination biomarkers in discrimination of COPD with community-acquired pneumonia and acute exacerbation of COPD[J]. Respir Res, 2022, 23(1):63-82. DOI
[10]	傅晶, 米东辉, 靳蓉晖, 等. 血嗜酸性粒细胞在慢性阻塞性肺疾病急性加重期的临床观察[J]. 中国实验诊断学, 2018, 22(1):61-63.
[11]	崔卫娜, 孟文霞, 赵雷, 等. 喉鳞癌组织miR-155-5p及其宿主长链非编码RNA MIR155HG表达临床意义[J]. 中华肿瘤防治杂志, 2018, 25(24):1693-1697.
[12]	TAO M, ZHOU Y, JIN Y, et al. Blocking lncRNA MIR155HG/miR-155-5p/-3p inhibits proliferation,invasion and migration of clear cell renal cell carcinoma[J]. Pathol Res Pract, 2020, 216(2):152803. DOI URL
[13]	MAAROUF M, CHEN B, CHEN Y, et al. Identification of lncRNA-155 encoded by MIR155HG as a novel regulator of innate immunity against influenza A virus infection[J]. Cell Microbiol, 2019, 21(8):e13036.
[14]	唐敏, 张玉高. 系统性红斑狼疮患者血清LncRNA MIR155HG的表达及临床意义[J]. 实用医学杂志, 2019, 35(2):213-216.
[15]	ARORA S, DEV K, AGARWAL B, et al. Macrophages:their role,activation and polarization in pulmonary diseases[J]. Immunobiology, 2018, 223(4-5):383-396. DOI URL
[16]	张进召, 刘松, 潘双, 等. 淡豆豉提取物通过调控LncRNA miR155HG/miR-409-3p表达抑制肺癌细胞的增殖、迁移和侵袭[J]. 中国老年学杂志, 2021, 41(14):3077-3082.
[17]	SONG J, WANG Q, ZONG L. LncRNA MIR155HG contributes to smoke-related chronic obstructive pulmonary disease by targeting miR-128-5p/BRD4 axis[J]. Biosci Rep, 2020, 40(3):BSR20192567. DOI URL

基因名称	上游引物（5'~3'）	下游引物（5'~3'）
lncRNA MIR155HG	CCCAAATCTAGGTTCAAGTTC	CATCTAAGCCTCACAACAAC
GAPDH	AGGTGAAGGTCGGAGTCAACG	AGGGGTCATTGATGGCAACA

基因名称	上游引物（5'~3'）	下游引物（5'~3'）
lncRNA MIR155HG	CCCAAATCTAGGTTCAAGTTC	CATCTAAGCCTCACAACAAC
GAPDH	AGGTGAAGGTCGGAGTCAACG	AGGGGTCATTGATGGCAACA

组别	例数	年龄/岁	性别		吸烟史/	BMI/（kg·m^-2）	WBC计数/（×10⁹/L）	NEUT%/%
组别	例数	年龄/岁	男/例	女/例	[例（%）]	BMI/（kg·m^-2）	WBC计数/（×10⁹/L）	NEUT%/%
AECOPD组	57	60.31±9.62	35	22	30（52.63）	23.56±2.07	9.34±2.51^*#	71.35±8.02^*#
稳定期组	60	59.48±9.07	39	21	24（40.00）	24.02±2.28	6.81±1.75^*	66.72±7.64^*
正常对照组	60	60.82±8.74	34	26	19（31.67）	23.19±2.40	6.07±1.68	59.46±7.31
统计值		0.328	0.881		5.359	2.036	42.433	35.981
P值		0.721	0.644		0.069	0.134	<0.001	<0.001
组别	ALT/	AST/	SCr/（μmol·L^-1）		BUN/（mmol·L^-1）	PCT/（ng·mL^-1）	CRP/	Fib/
组别	（U·L^-1）	（U·L^-1）	SCr/（μmol·L^-1）		BUN/（mmol·L^-1）	PCT/（ng·mL^-1）	（mg·L^-1）	（g·L^-1）
AECOPD组	34.03±11.25	30.51±9.94	67.43±21.05		6.03±1.98	1.50±0.41^*#	19.50±4.97^*#	4.42±1.13^*#
稳定期组	33.19±10.07	29.08±9.23	70.52±22.43		5.91±1.92	1.28±0.35^*	14.73±3.81^*	3.70±0.95^*
正常对照组	29.88±9.36	26.90±7.62	68.17±23.16		5.40±1.39	0.02±0.01	8.69±2.35	2.83±0.74
统计值	2.715	2.414	0.311		2.09	394.828	116.638	41.134
P值	0.069	0.093	0.734		0.127	<0.001	<0.001	<0.001

组别	例数	年龄/岁	性别		吸烟史/	BMI/（kg·m^-2）	WBC计数/（×10⁹/L）	NEUT%/%
组别	例数	年龄/岁	男/例	女/例	[例（%）]	BMI/（kg·m^-2）	WBC计数/（×10⁹/L）	NEUT%/%
AECOPD组	57	60.31±9.62	35	22	30（52.63）	23.56±2.07	9.34±2.51^*#	71.35±8.02^*#
稳定期组	60	59.48±9.07	39	21	24（40.00）	24.02±2.28	6.81±1.75^*	66.72±7.64^*
正常对照组	60	60.82±8.74	34	26	19（31.67）	23.19±2.40	6.07±1.68	59.46±7.31
统计值		0.328	0.881		5.359	2.036	42.433	35.981
P值		0.721	0.644		0.069	0.134	<0.001	<0.001
组别	ALT/	AST/	SCr/（μmol·L^-1）		BUN/（mmol·L^-1）	PCT/（ng·mL^-1）	CRP/	Fib/
组别	（U·L^-1）	（U·L^-1）	SCr/（μmol·L^-1）		BUN/（mmol·L^-1）	PCT/（ng·mL^-1）	（mg·L^-1）	（g·L^-1）
AECOPD组	34.03±11.25	30.51±9.94	67.43±21.05		6.03±1.98	1.50±0.41^*#	19.50±4.97^*#	4.42±1.13^*#
稳定期组	33.19±10.07	29.08±9.23	70.52±22.43		5.91±1.92	1.28±0.35^*	14.73±3.81^*	3.70±0.95^*
正常对照组	29.88±9.36	26.90±7.62	68.17±23.16		5.40±1.39	0.02±0.01	8.69±2.35	2.83±0.74
统计值	2.715	2.414	0.311		2.09	394.828	116.638	41.134
P值	0.069	0.093	0.734		0.127	<0.001	<0.001	<0.001

组别	例数	FEV₁/L	FEV₁/FVC%/%	lncRNA MIR155HG
AECOPD组	57	1.16±0.27^*#	39.25±6.17^*#	3.54±0.68^*#
稳定期组	60	1.65±0.29^*	59.62±7.58^*	2.74±0.57^*
正常对照组	60	2.53±0.31	84.76±8.04	1.03±0.12
F值		334.983	567.452	366.793
P值		<0.001	<0.001	<0.001